{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:47:59Z","timestamp":1778687279507,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01EX1015B"],"award-info":[{"award-number":["01EX1015B"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.tiv.2016.05.010","type":"journal-article","created":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T21:25:07Z","timestamp":1464038707000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Drug-induced phospholipidosis caused by combinations of common drugs in vitro"],"prefix":"10.1016","volume":"35","author":[{"given":"Mareike","family":"Glock","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Muehlbacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1678-6784","authenticated-orcid":false,"given":"Henoch","family":"Hurtig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Tripal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8096-3987","authenticated-orcid":false,"given":"Johannes","family":"Kornhuber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2016.05.010_bb0005","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.cbi.2008.10.057","article-title":"Lead-induced phospholipidosis and cholesterogenesis in rat tissues","volume":"179","author":"Ademuyiwa","year":"2009","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.tiv.2016.05.010_bb0010","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1016\/j.febslet.2006.08.061","article-title":"Drug-induced phospholipidosis","volume":"580","author":"Anderson","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.tiv.2016.05.010_bb0015","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.tiv.2015.01.014","article-title":"Predicting in vivo phospholipidosis-inducing potential of drugs by a combined high content screening and in silico modelling approach","volume":"29","author":"Bauch","year":"2015","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.tiv.2016.05.010_bb0020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084967","article-title":"Polypharmacy patterns: unravelling systematic associations between prescribed medications","volume":"8","author":"Calder\u00f3n-Larra\u00f1aga","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tiv.2016.05.010_bb0025","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.taap.2013.03.010","article-title":"In silico modeling to predict drug-induced phospholipidosis","volume":"269","author":"Choi","year":"2013","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.tiv.2016.05.010_bb0030","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/0006-2952(74)90174-9","article-title":"Lysosomotropic agents","volume":"23","author":"De Duve","year":"1974","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tiv.2016.05.010_bb0035","series-title":"Polypharmacy and Medicines Optimisation","author":"Duerden","year":"2013"},{"key":"10.1016\/j.tiv.2016.05.010_bb0040","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S1359-6446(05)03681-0","article-title":"Role of pharmacologically active metabolites in drug discovery and development","volume":"11","author":"Fura","year":"2006","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tiv.2016.05.010_bb0045","first-page":"1","article-title":"Prescription drug use continues to increase: US prescription drug data for 2007\u20132008","volume":"42","author":"Gu","year":"2010","journal-title":"NCHS Data Brief"},{"key":"10.1016\/j.tiv.2016.05.010_bb0050","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e6341","article-title":"Adapting clinical guidelines to take account of multimorbidity","volume":"345","author":"Guthrie","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.tiv.2016.05.010_bb0055","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","article-title":"The rising tide of polypharmacy and drug\u2013drug interactions: population database analysis 1995\u20132010","volume":"13","author":"Guthrie","year":"2015","journal-title":"BMC Med."},{"key":"10.1016\/j.tiv.2016.05.010_bb0060","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/019262339702500111","article-title":"Cationic amphiphilic drug-induced phospholipidosis","volume":"25","author":"Halliwell","year":"1997","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.tiv.2016.05.010_bb0065","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/tx9003825","article-title":"Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds","volume":"23","author":"Hanumegowda","year":"2010","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.tiv.2016.05.010_bb0070","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00103-008-0514-9","article-title":"Entwicklung der S3- und Nationalen Versorgungs-Leitlinie Depression","volume":"51","author":"H\u00e4rter","year":"2008","journal-title":"Bundesgesundheitsbl. Gesundheitsforsch. Gesundheitsschutz"},{"key":"10.1016\/j.tiv.2016.05.010_bb0075","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jpba.2011.11.033","article-title":"Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals","volume":"61","author":"Jiang","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.tiv.2016.05.010_bb0080","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0165-0327(93)90026-G","article-title":"Special issue toward a new psychobiology of depression in womensex and depression in the National Comorbidity Survey I: lifetime prevalence, chronicity and recurrence","volume":"29","author":"Kessler","year":"1993","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.tiv.2016.05.010_bb0085","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0031-6997(25)00049-3","article-title":"Cationic amphiphilic drugs and phospholipid storage disorder","volume":"42","author":"Kodavanti","year":"1990","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.tiv.2016.05.010_bb0090","doi-asserted-by":"crossref","DOI":"10.4061\/2009\/598940","article-title":"Increased density of the liver and amiodarone-associated phospholipidosis","volume":"2009","author":"Kojima","year":"2009","journal-title":"Cardiol. Res. Pract."},{"key":"10.1016\/j.tiv.2016.05.010_bb0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000315101","article-title":"Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications","volume":"26","author":"Kornhuber","year":"2010","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.tiv.2016.05.010_bb0100","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/0973-1229.104497","article-title":"Polypharmacy in psychiatry: a review","volume":"11","author":"Kukreja","year":"2013","journal-title":"Mens Sana Monogr."},{"key":"10.1016\/j.tiv.2016.05.010_bb0105","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/j.tiv.2011.06.017","article-title":"Evaluation and validation of multiple cell lines and primary mouse macrophages to predict phospholipidosis potential","volume":"25","author":"LeCureux","year":"2011","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.tiv.2016.05.010_bb0110","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1758-2946-4-2","article-title":"Predicting the mechanism of phospholipidosis","volume":"4","author":"Lowe","year":"2012","journal-title":"J. Cheminf."},{"key":"10.1016\/j.tiv.2016.05.010_bb0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/10408447509164014","article-title":"Drug-induced phospholipidoses","volume":"4","author":"L\u00fcllmann","year":"1975","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.tiv.2016.05.010_bb0120","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/0006-2952(78)90435-5","article-title":"Lipidosis induced by amphiphilic cationic drugs","volume":"27","author":"L\u00fcllmann","year":"1978","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.tiv.2016.05.010_bb0125","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1517\/14740338.2013.827660","article-title":"Clinical consequences of polypharmacy in elderly","volume":"13","author":"Maher","year":"2014","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.tiv.2016.05.010_bb0130","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1017\/S1461145713000837","article-title":"History, background, concepts and current use of comedication and polypharmacy in psychiatry","volume":"17","author":"M\u00f6ller","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.tiv.2016.05.010_bb0135","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/17425255.2.5.687","article-title":"In vitro assays and biomarkers for drug-induced phospholipidosis","volume":"2","author":"Monteith","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tiv.2016.05.010_bb0140","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/cmdc.201200306","article-title":"Identification of drugs inducing phospholipidosis by novel in vitro data","volume":"7","author":"Muehlbacher","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.tiv.2016.05.010_bb0145","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/toxsci\/kfm157","article-title":"In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid based methodologies","volume":"99","author":"Nioi","year":"2007","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.tiv.2016.05.010_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1293\/tox.21.9","article-title":"Drug-induced phospholipidosis\u2014pathological aspects and its prediction","volume":"21","author":"Nonoyama","year":"2008","journal-title":"J. Toxicol. Pathol."},{"key":"10.1016\/j.tiv.2016.05.010_bb0155","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/01.pra.0000265766.25495.3b","article-title":"Polypharmacy: when is it rational?","volume":"13","author":"Preskorn","year":"2007","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.tiv.2016.05.010_bb0160","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14740338.5.4.567","article-title":"Drug-induced phospholipidosis: issues and future directions","volume":"5","author":"Reasor","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.tiv.2016.05.010_bb0165","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2006.06.055","article-title":"Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes","volume":"48","author":"Rutledge","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.tiv.2016.05.010_bb0170","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.tins.2011.05.006","article-title":"Clarifying lysosomal storage diseases","volume":"34","author":"Schultz","year":"2011","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tiv.2016.05.010_bb0175","first-page":"447","article-title":"Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics","volume":"58","author":"Schulz","year":"2003","journal-title":"Pharmazie"},{"key":"10.1016\/j.tiv.2016.05.010_bb0180","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s40266-013-0064-1","article-title":"Studies to reduce unnecessary medication use in frail older adults: a systematic review","volume":"30","author":"Tjia","year":"2013","journal-title":"Drugs Aging"},{"key":"10.1016\/j.tiv.2016.05.010_bb0185","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s00249-008-0338-4","article-title":"Quantitative modeling of selective lysosomal targeting for drug design","volume":"37","author":"Trapp","year":"2008","journal-title":"Eur. Biophys. J. Biophys. Lett."},{"key":"10.1016\/j.tiv.2016.05.010_bb0190","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.tiv.2011.05.026","article-title":"High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis","volume":"25","author":"van de Water","year":"2011","journal-title":"Toxicol. in Vitro"},{"key":"10.1016\/j.tiv.2016.05.010_bb0195","series-title":"Guidelines for ATC classification and DDD assignment 2015, Oslo","year":"2014"}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233316300947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233316300947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T18:53:42Z","timestamp":1748976822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233316300947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":39,"alternative-id":["S0887233316300947"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2016.05.010","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced phospholipidosis caused by combinations of common drugs in vitro","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2016.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}